RxDoctor Payments Data

Robert Schubert, MD

Internal Medicine · Joliet, ILNPI 1972537884

Payments from drug & device makers

$1,848in general payments, 2019–2025

Across 81 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$550
  • Boehringer Ingelheim$455
  • AstraZeneca$186
  • Exact Sciences$102
  • Pfizer$101
  • Novo Nordisk$84
  • plus $369 from 12 others

What the payments were for

  • Food & beverage$1,842100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,848 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$68,327
Medicare patients
169
Services billed
1,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin128$137,863
EliquisApixaban68$86,889
MounjaroTirzepatide45$75,776
OzempicSemaglutide35$63,529
FarxigaDapagliflozin Propanediol37$51,601
JanuviaSitagliptin Phosphate18$28,440
RybelsusSemaglutide17$21,385
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,195
SymbicortBudesonide/Formoterol Fumarate12$7,471
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$6,905
Levothyroxine Sodium410$4,868
Nebivolol Hcl38$4,230
Rosuvastatin Calcium408$3,969
Atorvastatin Calcium358$3,455
Irbesartan125$2,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$455$137,863128 claims
PfizerEliquis$101$86,88968 claims
Novo NordiskOzempic, Rybelsus$84$84,91552 claims
AstraZenecaFarxiga, Symbicort$186$59,07249 claims
AbbVieSynthroid$64$1,96430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Joliet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →